JPRN-UMIN000005876已完成2 期
Combination treatment with TS-1+CDDP+Trastuzumab for unresectable HER 2 positive gastric cancer (A Phase II Study) - GCSPH
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. patient who has drug allergy as past history 2. patient who needs flucytosine, phenytoin, and Warfarin 3. patient who has active infectious disease with fever over 38 degree 4. patient who has severe complication (interstitial pneumonia, DM, renal failure, liver failure under bad control) 5. watery diarrhea 6. Pleural effusion and acites 7. patient who has heart disease(CHF, old MI, IHD, arrhythmia, and a valvular disease of the heart) 8.Uncontrolable hypertention 9. patient who has active double cancer 10. patient who want to be pregnant and /or pregnant woman 11. man who want to have a child 12. patient who was judged to be unsuitable for this clinical trial
研究者
相似试验
招募中
2 期
Clinical trial of TS-1 + CDDP + Trastuzumab-3 weekly cycle in HER2-positive advanced gastric cancerHER2 positive advanced gastric cancerJPRN-UMIN000009865Dokkyo Medical University8
已完成
2 期
Phase II trial of TS-1 plus Trastuzumab in patients with metastatic breast cancerbreast cancerJPRN-UMIN000004764Tokai University School of Medicine30
已完成
不适用
Trastuzumab incombination with S-1/CDDP of HER2-positive advanced gastric cancer: a phase II trial.HER2 positive gastric cancerJPRN-UMIN000005792Dept. of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences30
已完成
1 期
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)Advanced Breast CancerNCT01976169University of Texas Southwestern Medical Center29
已完成
1 期
Phase I study of TS-1+CDDP+PTX therapy in patients with advanced/recurrent gastric cancer (OGSG 0703)Patients with unresectable or metastatic gastric cancerJPRN-UMIN000000903OGSG6